Company: LIMN
Filing Date: 2025-05-06
Form Type: 8-K
Source: 0001104659-25-045127
Chunk: 0

Company: Liminatus Pharma, Inc.
Filing Date: 2025-05-06
Form: 8-K
Item: Item 2.01
Chunk 0
---
Item 2.01. Completion of Acquisition or Disposition
of Assets.

The disclosure set forth in
the “ Introductory Note” above is incorporated into this Item 2.01 by reference.

In connection with the vote
at the Special Meeting on March 4, 2025, public stockholders holding 59,844 Iris Class A Shares exercised their right to redeem
such shares for a pro rata portion of the funds in the trust account established at the consummation of Iris’ initial public offering
(the “ Trust Account”). As a result, approximately $702,359 (approximately $11.74 per share) was removed from the Trust Account
to pay such holders. Immediately after giving effect to the redemption of 59,844 Iris Class A Shares in connection with the Business
Combination, there were 114,633 public shares and 6,900,000 public warrants outstanding.

Upon the consummation of the
Business Combination, Iris’s Class A common stock, units and public warrants ceased trading on the OTC Pink Marketplace,
and ParentCo Common Stock and ParentCo Public Warrants began trading on The Nasdaq Stock Market (“ Nasdaq”) on May 1,
2025, under the symbols “ LIMN” and “ LIMNW,” respectively.

FORM 10 INFORMATION